D-0509-2023 Class II Ongoing

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0509-2023 was initiated by Direct Rx on Mar 22, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer. The recall status is ongoing. Affected quantity: 9 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 12, 2023
Initiation Date
Mar 22, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9 bottles

Product description

Alprazolam C-IV, 2 mg, 60 Tabs per bottle, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534, NDC 72189-121-60.

Reason for recall

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Distribution pattern

Nationwide in the USA

Code information

Lots: 03FE2319 Exp. 2/28/25, 13MY2217 Exp. 5/31/23

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0509-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0509-2023. Report a data issue: hello@regdatalab.com.